Q-omics provides the consensus-scored MAGEE2 profile across patient tissues and cancer cell-line models. MAGEE2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MAGEE2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MAGEE2 RNA expression shows 17,297 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCS, KIRC, and PDAC as cancer lineages where MAGEE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGEE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGEE2 survival associations across molecular data types. MAGEE2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGEE2 RNA expression–survival associations across cancer types. High MAGEE2 expression shows unfavorable associations in LIHC and STAD, but favorable associations in UCS, SCLC, CHOL and PRAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for MAGEE2 RNA expression.
This table summarizes MAGEE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MAGEE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGEE2 shows lower tumor expression in KIRC, COAD, READ, KIRP, HNSC and UCEC. The KIRC box plot shows higher MAGEE2 RNA expression in normal versus tumor tissue (log2 FC = −0.479, t-test p < 0.001).
This table shows molecular features associated with MAGEE2 in patient tissues and cancer cell lines. In patient samples, MAGEE2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGEE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SKIN.
